Renal Cancer - Results from #1700

Identification of a competing endogenous RNA network related to immune signature in clear cell renal cell carcinoma. December 29, 2021

Ablative therapies versus partial nephrectomy for small renal masses - A systematic review and meta-analysis. December 29, 2021

Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis. December 28, 2021

Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. December 28, 2021

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. December 27, 2021

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. December 27, 2021

Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma. December 27, 2021

Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. December 24, 2021

AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease. December 24, 2021

Identification of the Prognostic Value Among Suppressor Of Cytokine Signaling Family Members in Kidney Renal Clear Cell Carcinoma. December 23, 2021

Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. December 23, 2021

Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. December 22, 2021

2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. December 22, 2021

Risk models for recurrence and survival after kidney cancer: a systematic review. December 21, 2021

CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. December 21, 2021

Multimodal Deep Learning for Prognosis Prediction in Renal Cancer. December 20, 2021

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14). December 20, 2021

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery December 17, 2021

Development and Validation of a Predictive Model to Evaluate the Risk of Bone Metastasis in Kidney Cancer. December 17, 2021

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. December 17, 2021

Page 86 of 456